Correspondence 0001213900-25-011200 from Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc.
Date: Feb. 7, 2025 · CIK: 0001894525 · Accession: 0001213900-25-011200
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282324
Letter
Apimeds Pharmaceuticals US, Inc.
2 East Broad Street 2nd Floor
Hopewell, NJ 08425
February 7, 2025
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, DC 20549
Attention: Daniel Crawford
Laura Crotty
Re:
Apimeds Pharmaceuticals US, Inc. (the “Company”)
Registration Statement on Form S-1
(File No. 333-282324) (the “Registration Statement”)
Ladies and Gentlemen,
The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of effectiveness of the Registration Statement so that such Registration Statement will become effective as of 5:00 p.m. on Tuesday, February 11, 2025, or as soon thereafter as practicable.
Should you have any questions concerning this request, please contact our counsel, Nelson Mullins Riley & Scarborough LLP, by calling W. David Mannheim at (919) 329-3804 or Mike Bradshaw at (202) 689-2808.
Very truly yours,
Apimeds Pharmaceuticals US, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Apimeds Pharmaceuticals US, Inc.
2 East Broad Street 2nd Floor
Hopewell, NJ 08425
February 7, 2025
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, DC 20549
Attention:
Daniel Crawford
Laura Crotty
Re:
Apimeds Pharmaceuticals US, Inc. (the “Company”)
Registration Statement on Form S-1
(File No. 333-282324) (the “Registration Statement”)
Ladies and Gentlemen,
The Company hereby requests, pursuant to Rule 461
promulgated under the Securities Act of 1933, as amended, acceleration of effectiveness of the Registration Statement so that such Registration
Statement will become effective as of 5:00 p.m. on Tuesday, February 11, 2025, or as soon thereafter as practicable.
Should you have any questions concerning this request,
please contact our counsel, Nelson Mullins Riley & Scarborough LLP, by calling W. David Mannheim at (919) 329-3804 or Mike Bradshaw
at (202) 689-2808.
Very truly yours,
Apimeds Pharmaceuticals US, Inc.
By:
/s/ Erik Emerson
Name:
Erik Emerson
Title:
Chief Executive Officer